Brand name: Harmonise
Harmonise is a medicine containing the active ingredient(s) loperamide. On this page you will find out more about Harmonise, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: loperamide
Information for medicine and pack size:
Harmonise 2 mg film-coated tablet, 10
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Control and symptomatic relief of diarrhoea
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance |
Small round biconvex light blue film-coated tablets
Images are the copyright of the Pharmacy Guild of Australia |
| Dosage Form | Tablet, film coated |
| Route of administration | Oral |
| Medicine schedule |
10 tablets per pack: Pharmacy Medicine (Over the counter)
20 tablets per pack: Pharmacy Medicine (Over the counter)
8 tablets per pack: Pharmacy Medicine (Over the counter)
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 4 Years |
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 4 results
Changing Australian medicine names | Issue 3 | Volume 40 | Australian Prescriber | Australian Prescriber
The Therapeutic Goods Administration is changing the names of approximately 200 medicines.
Read more on Australian Prescriber website
Webinar recordings - health providers
This page contains links to recordings from webinars for Health Professionals held buy the Health Care Complaints Commission.
Read more on NSW Health Care Complaints Commission website
Department of Health | Legislative and Governance Forum on Gene Technology
The Legislative and Governance Forum on Gene Technology was previously known as the Gene Technology Ministerial Council (Ministerial Council). The then Ministerial Council was established by the intergovernmental Gene Technology Agreement 2001, to govern the activities of theGene Technology Regulator
Read more on TGA – Therapeutic Goods Administration website
Security Sensitive Biological Agents
This website provides information about the Security Sensitive Biological Agents (SSBA) Regulatory Scheme.
Read more on Department of Health website
Found 3 results
Changing Australian medicine names | Issue 3 | Volume 40 | Australian Prescriber | Australian Prescriber
The Therapeutic Goods Administration is changing the names of approximately 200 medicines.
Read more on Australian Prescriber website
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients | Cochrane
After kidney transplantation, patients receive a combination of immunosuppressive medications to prevent rejection of the transplanted kidney. These regimens usually contain a calcineurin-inhibitor (tacrolimus or cyclosporin A), corticosteroids and an antiproliferative agent (mycophenolic acid (MPA), e.g. mycophenolate mofetil (MMF), or azathioprine (AZA)). MPA is considered to be of stronger immunosuppressive potency than AZA, but the benefits on survival of the graft and its safe use over a long period of time are insufficiently understood.
Read more on Cochrane (Australasian Centre) website
Differences in Australian and New Zealand medicines funding policies | Issue 5 | Volume 37 | Australian Prescriber
Australia and New Zealand are well known internationally for having implemented national medicines policies that aim...
Read more on Australian Prescriber website
